Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T18:47:41.205Z.
Calculation as of: 2026-10-06T18:47:41.205Z.
Quote observation: 2026-10-06T18:45:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dfe3b7eb0a07bb41d8210bce1124860262d7a4d6e18a93ea2ad6da4bd4c55c28
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Praxis Precision Medicines, Inc.
Market Cap
$7.71B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.63B
EBITDA Yield
N/A
TTM Avg
1.69%
3Y Avg
1.69%
5Y Avg
1.69%
Market Cap
$7.83B
EBITDA Yield
2.29%
TTM Avg
2.88%
3Y Avg
2.88%
5Y Avg
2.88%
Market Cap
$7.33B
EBITDA Yield
45.08%
TTM Avg
34.53%
3Y Avg
34.53%
5Y Avg
15.09%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Praxis Precision Medicines, Inc. (PRAX) | $7.71B | N/A | N/A | N/A | N/A |
| Cytokinetics, Incorporated (CYTK)vs › | $7.63B | N/A | 1.69% | 1.69% | 1.69% |
| HealthEquity, Inc. (HQY)vs › | $7.63B | 5.76% | 5.61% | 4.47% | 3.98% |
| Caris Life Sciences, Inc. (CAI)vs › | $7.83B | 2.29% | 2.88% | 2.88% | 2.88% |
| Hinge Health, Inc. (HNGE)vs › | $7.55B | 1.34% | 1.35% | 0.86% | 0.86% |
| TG Therapeutics, Inc. (TGTX)vs › | $8.04B | 1.64% | 1.92% | 1.70% | 1.70% |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.33B | 45.08% | 34.53% | 34.53% | 15.09% |
| Oscar Health, Inc. (OSCR)vs › | $8.41B | 13.70% | 4.45% | 3.74% | 3.74% |
| Alkermes plc (ALKS)vs › | $7.02B | 2.21% | 5.56% | 8.89% | 6.62% |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.67B | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
